Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies.
about
Recent developments in drug discovery for leishmaniasis and human African trypanosomiasisLeishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatmentIdentification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screenMonitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparisonNovel compounds active against Leishmania major.Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B geneRandomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.Treatment strategies for mucocutaneous leishmaniasis.Treatment of visceral leishmaniasis.Laboratory-acquired parasitic infections from accidental exposures.Antileishmanial activities of stearylamine-bearing liposomesAntimony toxicity.A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasisDouble blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasisNaturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guideVisceral leishmaniasis in Malta--an 18 year paediatric, population based studyLeishmania and human immunodeficiency virus coinfection: the first 10 yearsHuman antiprotozoal therapy: past, present, and future.Construction of a Saccharomyces cerevisiae strain expressing the Leishmania major nucleoside hydrolase genePhosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.Leishmaniases of the New World: current concepts and implications for future researchRural campaign to diagnose and treat mucocutaneous leishmaniasis in Bolivia.Microscopy and polymerase chain reaction detection of Leishmania chagasi in the pleural and ascitic fluid of a patient with AIDS: Case report and review of diagnosis and therapy of visceral leishmaniasis.Therapeutic options for visceral leishmaniasis.Kala-azar in a Brazilian childNeglected tropical diseases: survey and geometry of randomised evidence.Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light.The Effect of Garlic Extract on Expression of INFγ And Inos Genes in Macrophages Infected with Leishmania majorCombination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.PROBLEMS IN MANAGEMENT OF KALA AZAR: EXPERIENCE FROM BIHAREvidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine AntimoniateClinicoepidemiological study of drug resistance in Indian kala-azar.Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model.
P2860
Q27011766-EDF5C171-218D-40CD-9762-DA1D994A0F64Q28082283-51F9A5EA-75DE-4E52-BDA1-B85F63412342Q28471705-70D127F3-D059-4A81-BD89-A71340407CC1Q28480699-93679F52-EBEB-4749-864E-FD9F22F8F3C4Q28487597-4C1C7C12-499C-4068-94F8-57D565699D9FQ30807168-C1E82CCF-D270-4FDC-839A-D7708F818BBBQ33283496-9E635228-4A03-4F6C-9CF3-A4F8A930138BQ33779256-6E6FF35E-48C8-4C45-AA74-69B275EA8C91Q33929843-650C6437-24A9-4280-A626-6E7EB4628854Q33929849-95AFB4A8-B2C5-4073-B131-B4E7C20A4AFBQ33975767-1E762B47-50DC-405B-8CDB-8C69813559CCQ33979887-3BC4A6A1-AF1E-4820-A480-247B2217ECC0Q34164336-C307C6EC-0230-432F-B334-47310467D88BQ34422191-A7F7AF60-3429-4642-9E09-3068D1246E1BQ34565059-4B16BA3C-2BC2-462C-881B-F8B9629341FCQ34883404-9D016F2B-5902-4BFE-9B9F-D1ECB5930679Q35122890-D43FDC23-E544-49C1-8DF1-AD8ECE79D020Q35130083-440C9005-FD08-466D-B471-F3F95D4CDA1CQ35160905-63F20E63-5EA8-41CE-9421-1F95E56A124AQ35266494-C7F9775F-430B-4D96-BD3F-0F6227292E23Q35374078-C5815A9E-8921-43D7-9BF2-714AD734ADDCQ35535171-6AF298BE-CCF6-4DC3-BCB2-9ABF676A8898Q35741614-E698C79D-DCD9-4BD5-BC83-94CC8A27E3BBQ35764349-10DB2D0E-D9F8-41FF-BEE1-A7F2BE96143EQ35897139-077C02D0-D6AE-422B-BC54-66A5379B8539Q36159786-8D469C0C-6A5E-4A6C-BD3C-62404109282AQ36321435-240FEB9A-54D9-4652-85E2-7BCB0ECE57B8Q36640255-5D1C1430-647D-45BE-8B3F-9575657CC84DQ36794524-652F4C50-76A8-4784-A834-13ADBB14B5EBQ37045139-A6E6E571-3388-41C9-B1BE-9B1A013E45D4Q37333942-8ACF127A-0BEA-442A-AA23-55F7019F7679Q37694176-50B74FED-EFFA-4AAF-B4A0-27CBD5665096Q38054293-84375AB4-5C25-4D92-BFA5-2880A29D13CCQ39176904-7AA82ED2-0EB8-4889-9CA1-D86A1420B155Q39394132-C0DE5CE6-88D7-42F0-BD88-DF8F0E961C9FQ39955167-350A4751-C16A-40DA-83A0-61AA55E002C9Q40605380-C6C9FFEE-4273-415F-924E-51737AB02AA2Q41180486-D3CF930F-47B0-44D0-BC6B-E3A81BDC621BQ41763228-814C6596-9127-4D16-9C07-128ACD5A00F9Q55054442-2798C5E5-4618-4965-AD87-7D9F382EC179
P2860
Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies.
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Recommendations for treating l ...... of pertinent clinical studies.
@ast
Recommendations for treating l ...... of pertinent clinical studies.
@en
Recommendations for treating leishmaniasis with sodium stibogluconate
@nl
type
label
Recommendations for treating l ...... of pertinent clinical studies.
@ast
Recommendations for treating l ...... of pertinent clinical studies.
@en
Recommendations for treating leishmaniasis with sodium stibogluconate
@nl
prefLabel
Recommendations for treating l ...... of pertinent clinical studies.
@ast
Recommendations for treating l ...... of pertinent clinical studies.
@en
Recommendations for treating leishmaniasis with sodium stibogluconate
@nl
P1476
Recommendations for treating l ...... of pertinent clinical studies.
@en
P2093
Herwaldt BL
P304
P407
P577
1992-03-01T00:00:00Z